Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on

Summary

Roche CEO Thomas Schinecker stated during Q2 earnings call that the company has 19 investigational medicines potentially launching by 2030 and feels well-positioned for growth into the next decade without pressure to acquire additional programs.